Articles tagged with Cancer Immunology
MUSC researcher Haizhen Wang receives R37 grant to investigate CDK6's role in T-cell acute lymphoblastic leukemia, a aggressive cancer. The research aims to understand how the immune system can be used to reduce leukemia progression.
Researchers found that the gene TCF-1 regulates specific Treg cells, leading to more severe and inflammatory colon cancers. Without TCF-1, these cells become activated and gain a gut-homing feature, resulting in harsher cancer outcomes.
Researchers have created a new technology to enhance therapeutic antibodies' ability to attack blood cancer cells by leveraging the human immune system. This approach combines IgM and IgG antibodies, resulting in a single molecule with increased complement activation.
A new study found that immune checkpoint inhibitors are effective against HPV-positive head and neck cancers, with a potential therapeutic vaccination approach also being explored. Researchers discovered tumor-specific CD8 T cells in tumors from patients, which could provide a proliferative burst in response to PD-1 blockade.
Researchers identified DSS1 as a critical protein in breast cancer progression and found that depleting it makes cancer cells more responsive to lower doses of anti-cancer drugs. This technique may reduce drug-induced side effects in breast cancer patients, providing a safer treatment option.
Researchers at H. Lee Moffitt Cancer Center & Research Institute found that combining checkpoint inhibitors with adoptive cell therapy improves treatment outcomes for patients with non-small cell lung cancer. The study showed promising anti-tumor activity, with 11 out of 16 patients experiencing tumor regression.
Researchers discovered that hypoxia induces regional variations in gene-expression patterns in pancreatic cancer, with specific subpopulations of cancer cells surviving under hypoxic conditions. These findings suggest a link between hypoxia and aggressive tumor behavior, highlighting the need for targeted treatments.
A recent study published in eLife found that chronic inflammation can turn the skin's protective IgE antibody into a tumor promoter. In mice with cancer-causing mutations, chronic activation of IgE by inflammation supported the growth of precancerous skin cells into tumors.
A new study shows an association between a family history of cancer and childhood asthma diagnosis in over 20% of children, highlighting the importance of extra asthma screening efforts.
Zachary Schug receives $2,679,000 NIH award to study link between high sugar/fat diet, alcohol use and cancer. He aims to uncover molecular mechanisms underlying this connection and develop novel therapies.
Researchers found that mitochondrial fission factor is a key regulator of cancer cell survival and proliferation. The protein's interaction with VDAC1 is critical for tumor cell growth, but disrupting this complex can activate mechanisms of mitochondrial cell death.
The study found that ARID1A controls the genome-wide positioning of condensin II, a complex regulating gene expression through organizing chromosome structure. This loss affects global gene expression, with broad consequences for cancer types, especially ovarian cancer.
Researchers discovered that BH4 regulates T cell activity, suppressing inflammation in autoimmune conditions and enhancing responses in cancer. A new therapeutic approach targets the same pathway to treat a range of diseases.
Wherry and Matthew Hellmann have received $1.25 million to test a combined approach of modifying epigenetic pathways and PD-1 pathway blockade therapy to improve exhausted T cell reinvigoration. This award recognizes their collaborative work on a fundamental goal of cancer researchers.
M. Celeste Simon, a renowned Penn Cancer biologist, has been awarded the National Cancer Institute Outstanding Investigator Award. She is recognized for her groundbreaking research on cancer cell metabolism and its applications in treating clear cell renal cell carcinoma.
The Pew Charitable Trusts has announced the selection of five early-career cancer researchers, who will receive four years of flexible funding to conduct their work. The selected scientists aim to unravel the mysteries of cancer by studying medulloblastoma recurrence and developing new immune therapies against pancreatic cancer.
Researchers warn that even mild chronic cold stress is skewing results in studies of cancer, inflammation, and other fields. The National Research Council recommends a temperature range of 20-26 degrees C for mouse housing.
Researchers found that cancer cells hijack glucose to alter immune cells, leading to reduced T cell effectiveness. However, they also discovered a potential metabolic pathway to make T cells resistant to glucose restriction, which could improve cancer treatment outcomes.
Researchers from USC Norris Comprehensive Cancer Center have discovered that herpesvirus proteins activate the RIG-I receptor through deamidation, a process that could be exploited to bolster immunity against infection. The study identifies the first enzyme responsible for protein deamidation in eukaryotes.
Dr. Elizabeth Jaffee receives the AACR-Joseph H. Burchenal Award for her pioneering contributions to immunotherapies for breast and pancreatic cancers, leading to improved treatments and patient outcomes. Her work also focuses on establishing biomarkers of tumor microenvironment reprogramming.
A study published in Nature Immunology has identified two key proteins, KLF2 and S1P1, that influence immune response strategies. The findings suggest that cytokines play a major role in determining whether lymphocytes become resident memory cells or recirculate.
A LSUHSC researcher has been awarded a five-year, $1.5 million NCI grant to investigate the connection between chronic inflammation and cancer development. The project aims to understand how p53 dysfunction in normal cells surrounding cancer cells can lead to an inflammatory microenvironment that supports tumor growth.
Bioinformatician Professor Terry Speed has received a 2012 Victoria Prize for Science and Innovation for using statistics to solve biomedical research questions. His work has led to new techniques in cancer, infectious diseases, immunology, and inherited diseases.
Researchers at IRIC discovered a protein, RSK, that contributes to chemoresistance in melanoma. Blocking its action could lead to improved treatment of skin cancers.
Research suggests that high levels of circulating DNA, specifically human telomerase reverse transcriptase (hTERT), can indicate a faster progression of lung cancer and lower overall survival. Patients with lower hTERT levels had improved time to progression and higher overall survival rates compared to those with higher levels.
Agricultural Research Service chemist Thomas Wang found that resveratrol, a bioactive compound in grapes and plant foods, can inhibit cancer cell growth but also increase tumor vessel development with prolonged exposure. The study suggests that diet complexity and gene expression are key layers in cancer development.
Scientists at the University of Montreal and Mount Sinai Hospital have identified a new target for cancer cure. Inhibiting the dimerization of RAF protein kinase may block its activation, stopping cancer cells from growing. This breakthrough has the potential to lead to novel anti-cancer agents with unprecedented precision.
A Montreal-based research team has identified a new mechanism controlling NK cell activity, which could improve the treatment of cancers and infectious diseases. The team's breakthrough discovery reveals that the CRACC molecule enhances NK cell killer function.
Researchers have discovered a new mechanism that regulates the production of type I interferon, an important protein for clearing viral infections. This mechanism involves a protein-protein interaction between surface receptors on plasmacytoid dendritic cells and class I major histocompatibility complex molecules.
Researchers develop novel viral vector delivery system to alert immune system against cancer cells, bypassing the tumor's immune-suppressive mechanisms. The approach has potential for treating persistent infections and cancers.
The Ludwig Institute has expended over $1.1 billion in cancer research since its inception, and the new gift will ensure annual research funds of approximately $2 million per center. The six US institutions will collaborate on a powerful force in cancer research.
The Ludwig Fund has given a record-breaking $120 million to support cancer research at six top US institutions. The fund will provide annual research grants of approximately $2 million per center in perpetuity.
The AIDS and Cancer Specimen Bank at UCSF is expanding its operations with new technologies and a central coordinating office. The bank now serves over one million specimens from around the world, including China, Thailand, and South America.
Researchers at University of Illinois Chicago have discovered a way to render cancer cells more susceptible to immunological attacks and chemotherapy. By inserting the E1A gene into malignant cells, they can prevent tumor cells from blocking immune defenses, paving the way for new treatments.